lemme glp-1 daily Reset™ Production Support Capsules Reset™, Support GLP-1 Production, 60

Obesity and associated metabolic disorders such as type 2 diabetes mellitus and polycystic ovary syndrome are rising globally, contributing to infertility and adverse pregnancy outcomes

Methods Adults (18 years old) with T2D required at least one prescription for injectable semaglutide at index date (treatment switch), at least one prescription for any other GLP-1 RA in the previous 365 days, a baseline HbA1c and/or weight measurement in the 90 days pre-index and a follow-up measurement at 180 and 365 days post-index

There are currently two major players with a decisive head start in the obesity drug space: Eli Lilly (LLY) and Novo Nordisk (NVO)

The Risks: Unknown ingredients and contamination Incorrect dosages and life-threatening side effects No regulatory oversight or safety data Why This Is Critical: Patients are bypassing pharmacies and getting injections from sketchy online vendors This undermines real GLP1 therapies and can lead to serious harm As healthcare professionals, we must: Ask patients about the source of their medications Report adverse reactions to MedWatch Educate our patients about safe access and real prescriptions Lets advocate for ethical prescribing and responsible patient care in the GLP1 era

Weight loss injections seem to be more popular, but "compounded" versions of these drugs can vary in how people access them.